Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT02657928
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT02648477
- Locations
- 🇺🇸
City of Hope Corona, Corona, California, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope South Pasadena, South Pasadena, California, United States
A Comparison of Letrozole and Clomifene Citrate
- Conditions
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 40
- Registration Number
- NCT02647424
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
Graceful Lifestyle Changes Study for PCOS and Infertility
- Conditions
- Interventions
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 240
- Registration Number
- NCT02630485
Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- Gary Schwartz
- Registration Number
- NCT02619669
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2019-07-23
- Target Recruit Count
- 25
- Registration Number
- NCT02619162
- Locations
- 🇪🇸
Hospital de La Princesa, Madrid, Spain
🇪🇸Clínica Quirón, Madrid, Spain
🇪🇸Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
- Conditions
- Interventions
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 131
- Registration Number
- NCT02600923
- Locations
- 🇧🇷
Hospital Sao Lucas da PUCRS / Uniao Brasileira de Educacao e Assistencia, Porto Alegre, RIO Grande DO SUL, Brazil
🇦🇷Instituto de Cardiologia y Cirugia Cardiovascular, Santa Fe, Argentina
🇧🇷Hospital Da Cidade De Passo Fundo, Passo Fundo, RIO Grande DO SUL, Brazil
Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- ARCAGY/ GINECO GROUP
- Target Recruit Count
- 120
- Registration Number
- NCT02585388
- Locations
- 🇫🇷
CHU de Grenoble, Grenoble, France
🇫🇷CHD Vendée, La Roche sur Yon, France
🇫🇷Centre Hospitalier Lyon Sud, Pierre-Bénite, France
Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Poly Cystic Ovary Syndrome ( PCOS )
- Conditions
- Interventions
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2015-09-16
- Lead Sponsor
- mostafa gomaa hamid halawa
- Target Recruit Count
- 110
- Registration Number
- NCT02551367
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Fondazione Sandro Pitigliani
- Target Recruit Count
- 115
- Registration Number
- NCT02549430
- Locations
- 🇮🇹
Azienda Ospedaliera Papa Giovanni Xxiii, Bergamo, Italy
🇮🇹Istituto Europeo Oncologia, Milano, Italy
🇮🇹Ospedale Antonio Perrino, Brindisi, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.